Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc., a clinical stage pharmaceutical company, has published its first-quarter 2024 financial results showing a decrease in total revenue by 15% compared to the previous year, with significant drops in both Canadian and U.S. markets. The company reported a 33% decline in gross margin, but operating expenses also fell by 11%, leading to a 10% reduction in net loss. An investor conference call to discuss these results is scheduled for June 6th, 2024.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
